Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › INDOCO

INDOCO

Indoco Remedies Limited
Micro-capPharma ↗

What the six lenses say about INDOCO — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹250.7
2026-09-08
VWAP · 1Y anchor
₹248
+1.1% from VWAP
P/E · TTM
-24.3×
TTM EPS ₹-10.3
52-week range
60%
position low→high
RSI(14)
57
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How INDOCO’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.0
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD9100›

The actual numbers

Price vs VWAP (1y)+1.1%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+7.4%
Price vs 50-EMA+6.8%
RSI(14)57
RS vs Nifty 500 · 3M+21.2%
RS vs sector · 3M+15.2%
52-week range60%
Volume vs 30d avg0.22×
Volume vs 60d avg0.21×
ATR(14) · volatility16.4
Bollinger width · vol contraction0.309
FundamentalD219›

The actual numbers

Return on equity (ROE)-10.4%
Operating margin0.9%
Net margin-5.3%
Revenue growth · YoY+10.9%
Debt / equity1.16×

Full 8-quarter history in the financials table below.

ValuationD640›

The actual numbers

P/E (TTM)-24.3×
TTM EPS₹-10.3
52-week range60%
CatalystD433›

The actual numbers

Earnings & momentum27
Capital actions24
Governance75

Every filing in the corporate-announcements panel below.

FlowD750›

The actual numbers

Promoter holding58.9%
Delivery · 30d avg40.2%
Up/down-day asymmetry0.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D7 ) ÷ 2 = 8.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 8.0/10
Conviction score95/100›
TechnicalD9›
FundamentalD2›
ValuationD6›
CatalystD4›
FlowD7›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-4.0pp
+4.3pp
+16.5pp
+22.8pp
+29.1pp
-5.5pp
Nifty 500
Broad-market baseline
-4.1pp
+4.3pp
+15.4pp
+21.2pp
+23.4pp
-10.7pp
Sector
Own-sector index
—
—
+12.6pp
+15.2pp
+10.3pp
-31.5pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

INDOCO daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
250.70-11.81

Relative strength

RS vs baseline · rebased to 100

INDOCO ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
68.25-2.91

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)431433411390440485445476
↳ change QoQ—+0.3%-5.1%-5.0%+12.8%+10.2%-8.2%+7.0%
EBITDA (₹cr)494214-118433250
EBITDA margin11.3%9.7%3.4%-0.3%4.1%8.9%7.2%10.5%
PAT (₹cr)2-10-28-41-36-9-29-24
↳ change QoQ—-650.0%-183.7%-44.4%+12.2%+75.0%-222.2%+17.2%
Net margin0.4%-2.3%-6.9%-10.5%-8.2%-1.9%-6.5%-5.0%
EPS (₹)0.20-1.09-3.08-4.38-3.88-0.86-3.23-2.34
D/E————————
YoY growth · Mar '26Revenue +22.1% YoYPAT +41.5% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 10 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    LOWgovernance
    Agreements
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Jul '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Jul '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 17 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 28 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 May '26
    LOWgovernance
    Agreements
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 May '26
    LOWgovernance
    Demise
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds INDOCO

Mutual funds holding INDOCO (3)

FundWeightAUM ₹crGrade
ICICI Pru Pharma Healthcare Diag Gr0.54%6,803
DSP Healthcare Fund Reg Gr1.96%3,639
DSP Multicap Reg Gr0.56%2,998

ETFs holding INDOCO (0)

No tracked ETF holds INDOCO ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma